Banco Santander announces third-quarter earnings
Q3 Financial Performance: Banco Santander reported a Q3 GAAP EPS of €0.23, with net interest income of €10.35 billion, reflecting a 2% year-over-year increase. Profit attributable to the parent reached €3,504 million, marking a sixth consecutive quarterly record.
CET1 Ratio and Profit Growth: The CET1 ratio stood at 13.1% at the end of September 2025, slightly above the target range. Year-to-date, attributable profit increased by 11% to €10,337 million, driven by strong performances across revenue lines and controlled costs.
Impact of Argentina: Despite challenges in Argentina, profit growth remained resilient, with a 4% increase when excluding its impact. The bank's solid net fee income and lower provisions contributed to overall profitability.
Future Outlook: Banco Santander's strong profit growth across global businesses positions it well to meet its 2025 targets, supported by a solid increase in revenue and flat costs in real terms.
Trade with 70% Backtested Accuracy
Analyst Views on SAN
About SAN
About the author

- Climate Target Controversy: Banco Santander is facing strong criticism from climate activists after adjusting and diluting its emissions targets, which could negatively impact its reputation among ESG investors, particularly when compared to peers like BNP Paribas and HSBC.
- New Headquarters Initiative: The bank's decision to relocate its Brazilian headquarters to the sustainability-focused, tech-enabled Campus JK is framed as a long-term investment in operational efficiency and digital capabilities, potentially attracting talent and enhancing market competitiveness.
- Increased Financial Flexibility: With an 11.4% growth in earnings over the past year, Banco Santander has gained more flexibility to fund projects like Campus JK while also absorbing one-off costs associated with its transformation efforts.
- Regulatory and Reputational Risks: The dilution of emissions targets may heighten Banco Santander's reputational and regulatory risks, especially as global peers face similar scrutiny, which could influence future funding costs and capital allocation decisions.
- Chairman of Spain's Santander: The chairman has announced that they are estimating the closing of the Webster deal in the third quarter (Q3).
- Implications for Santander: This move is part of Santander's strategic plans and may impact their financial performance and market positioning.

- Chairman of Spain's Santander: The chairman has confirmed that the bank will continue to maintain its capital allocation to business at 20%.
- Focus on Capital Maintenance: The emphasis is on sustaining capital levels to support business operations effectively.
- Chairman of Spain's Santander: The chairman has stated that the bank is not considering launching any new products in the near future.
- Focus on Current Operations: The bank's current strategy appears to prioritize existing operations rather than expanding its product offerings.
- Profit Growth Outlook: Santander Bank announced at its Investor Day in London that it expects to achieve over €20 billion in profit by 2028, reflecting strong profitability and market confidence.
- Revenue and Cost Management: The company plans to achieve mid-single-digit revenue growth and reduce costs annually from 2026 to 2028 to ensure it meets its profit targets, thereby enhancing overall financial health.
- Customer Base Expansion: Santander anticipates growing its customer base to over 210 million across Europe and the Americas by 2028, up from 180 million at the end of 2025, indicating the effectiveness of its market penetration strategy.
- Dividend Policy Adjustment: The board proposed a final cash dividend of €0.125 per share against 2025 profits, with a total expected cash dividend of €0.24 per share for 2025, representing over a 14% increase from 2024, and plans to more than double the cash dividend per share by 2028.
- Vir Biotechnology's Market Potential: The company is showing signs of becoming a significant player in the cancer drug market.
- Stock Reaction: A recent stock reaction indicates positive investor sentiment towards Vir Biotechnology's prospects.






